SYN X makes progress with CHF (congestive heart failure) and Alzheimer's tests
This article was originally published in Clinica
SYN X Pharma has received an allowance for US patent for a 15-minute, point-of-care test for congestive heart failure (CHF). The test, claimed the firm, is the first to combine, in a single test, two known methods for diagnosing the disease - a marker for myocardial cell injury and a marker for left ventricular overload. Together these indicators for dying cells and heart enlargement provide more accurate patient prognosis, said Toronto, Canada based SYN X.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.